Personalized surgery-focused treatment plan for relapsed brain cancer
Part of Cancer clinical trials.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have medulloblastoma or ependymoma that has returned (first or second relapse) and was confirmed by prior tissue testing
- The tumor must be reachable enough for the doctors to do a surgery or biopsy and collect enough tissue for study
- You must have had at least one previous treatment, and you must have recovered from past treatment side effects before enrolling
- If you had radiation, it must be at least 12 weeks since key radiation, and at least 14 days since any small-port palliative radiation
- Age must be 12 months to 39 years, and your general health tests must be strong enough (blood counts, kidney and liver tests)
- You must not be on other cancer medicines during the study (steroids are allowed if dose is stable or decreasing)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
This study looks at genetic (DNA/molecular) features of malignant brain tumors in children. It may help doctors better understand tumor risk patterns and guide future treatment planning.
This study looks at how young people with certain brain tumors respond to treatment. It aims to understand why some tumors resist therapy, which may help improve future treatments.
This study tests a new way to choose treatment for people with brain tumors that have not responded to standard therapies. Your tumor sample is analyzed in the lab to find which drugs might work best for you, and then you receive a personalized treatment plan.
This Phase 2 trial tests how doctors choose treatment for infants and young children with newly diagnosed medulloblastoma, based on MRI/CSF staging and lab testing of the tumor. It may help by matching therapy intensity to the child’s specific risk level and tumor type.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
Hear when a new Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.